GSK ORD 31 1/4P news, videos and press releases
For more news please use our advanced search feature.
GSK ORD 31 1/4P - More news...
GSK ORD 31 1/4P - More news...
- GSK prepares US for 2022-23 flu season with over 50 million influenza vaccine doses
- GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
- IDEAYA Announces Development Candidate Nomination of a Potential First-in-Class Pol Theta Helicase Inhibitor in Collaboration with GSK
- Ascential Digital Commerce and GSK Consumer Healthcare Announce Launch of Ascential Digital Commerce Connect at Cannes Lions
- Thinking about trading options or stock in Intel Corp, ConocoPhillips, Altria Group, Marathon Petroleum, or GSK?
- Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis
- GSK announces US FDA approval of PRIORIX for the prevention of measles, mumps and rubella in individuals 12 months of age and older
- /C O R R E C T I O N -- GSK Consumer Healthcare/
- The Food Fight is Over: TUMS® Declares It is Time to Love Food Back
- GSK Plc - Director/PDMR Shareholding
- Voltaren Teams Up with Actress Jennie Garth to Support Caregivers Nationwide
- New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
- Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
- Alacer Corp. Launches New Eco-Conscious Toothpaste Brand Natean®
- Thinking about buying stock in Ford Motor, ALJ Regional Holdings, Occidental Petroleum, GlaxoSmithKline, or Gran Tierra Energy?
- Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKline
- Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis Shows
- Thinking about trading options or stock in Activision Blizzard, GlaxoSmithKline, Take-Two Interactive, Phillips 66, or Apple?
- GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
- Sensodyne® Repair and Protect with Deep Repair is Proud to Deliver a Minty & Whitening Toothpaste, Just in Time for National Coffee Day
- GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
- GSK and CureVac to Develop Next Generation MRNA COVID-19 Vaccines
- FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
- GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
- US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
- Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
- Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual Meeting
- GSK Submits Filing to FDA for Trelegy Ellipta Use in Patients With Asthma
- Phase 3 PRIMA trial of Zejula® (niraparib) is the first study to show a PARP inhibitor significantly improves PFS, regardless of biomarker status, when given as monotherapy in women with first-line platinum responsive advanced ovarian cancer
- GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC)